Vimarsana
Biggest News Aggregation in the World

Page 29 - Accessed March News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Accessed March. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Accessed March Today - Breaking & Trending Today

Study Details Prevalence of Diastolic Dysfunction in Adults Survivors of Childhood Cancer - Vimarsana News

Study Details Prevalence of Diastolic Dysfunction in Adults Survivors of Childhood Cancer

An analysis of data from the St. Jude Lifetime Cohort Study provides new insight into the risk of long-term diastolic dysfunction associated with cardiotoxic cancer therapies in adult survivors of childhood cancer.

New Data Presented at AD/PD™ 2023 Show Biogen's BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer's Disease - Vimarsana News

New Data Presented at AD/PD™ 2023 Show Biogen's BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer's Disease

The BIIB080 Phase 1b clinical study is the first to show a reduction of this magnitude in tau PET across brain regionsPhase 1b Study of BIIB080 showed dose-dependent and sustained reduction of tau... | March 29, 2023

New Data Presented at AD/PD™ 2023 Show Biogen's BIIB080 - Vimarsana News

New Data Presented at AD/PD™ 2023 Show Biogen's BIIB080

The BIIB080 Phase 1b clinical study is the first to show a reduction of this magnitude in tau PET across brain regionsPhase 1b Study of BIIB080 showed...

Biogen Inc.: New Data Presented at AD/PD 2023 Show Biogen's BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer's Disease - Vimarsana News

Biogen Inc.: New Data Presented at AD/PD 2023 Show Biogen's BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer's Disease

The BIIB080 Phase 1b clinical study is the first to show a reduction of this magnitude in tau PET across brain regionsPhase 1b Study of BIIB080 showed dose-dependent and sustained reduction of tau protein

AskBio to Present Phase 1b Results Investigating AB-1005 (formerly AAV2-GDNF) as Treatment for Parkinson's Disease at AD/PDTM 2023 International Conference on Alzheimer's and Parkinson's Diseases - Vimarsana News

AskBio to Present Phase 1b Results Investigating AB-1005 (formerly AAV2-GDNF) as Treatment for Parkinson's Disease at AD/PDTM 2023 International Conference on Alzheimer's and Parkinson's Diseases

/PRNewswire/ -- Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, will...